Opinion|Videos|November 15, 2024
Biomarker Testing in NSCLC: Best Practices for Personalized Medicine
Panelists discuss how the interpretation of HER2 IHC scores informs treatment decisions in NSCLC, including adherence to ASCO/CAP guidelines and strategies for managing equivocal results.
Advertisement
Episodes in this series
- (Rohit asks Levy) How do you interpret HER2 IHC scores when determining treatment for patients with NSCLC? How does this influence your therapeutic decisions?
- When applying HER2 scoring and considering ASCO/CAP guidelines in NSCLC, do you follow breast cancer scoring guidelines, or have you considered using gastric cancer scoring?
- How do you interpret equivocal or borderline results? Are there any specific considerations or additional testing you recommend for this group?
Advertisement
Related to this article
William A. Hall, MD, explains how fewer visits, no concurrent chemotherapy, and adaptive MRI guidance may have preserved quality of life with SBRT.
“We are not just treating the cancer; we are treating the patient,” said Marcio A. Fagundes, MD.
Poster presentations at IMS 2026 highlighted the use of venetoclax, daratumumab, and different combination regimens across various treatment settings.
Patient enrollment of the phase 3 IDeate-Lung02 trial assessing I-DXd vs chemotherapy in relapsed ES-SCLC will continue following the withdrawal.
Developers have resubmitted the biologics license application for tabelecleucel following feedback from a Type A meeting in April 2026.
William A. Hall, MD, discussed how preoperative SBRT may serve as a platform for novel systemic therapies in pancreatic adenocarcinoma.
At 8 years, SBRT and radical prostatectomy had similar disease control in the PACE-A trial, with less urinary incontinence after SBRT.
Chih-Yi “Andy” Liao, MD, discusses early clinical data for KRAS G12C and G12D inhibitors in cholangiocarcinoma, noting that trials are just getting started.
Advertisement
Advertisement
Trending on CancerNetwork
1
Where Does Intensity-Modulated Proton Therapy Fit in Prostate Cancer?
2
Multimodal Biopsy Combo Shows Low Morbidity in Suspected Prostate Cancer
3
FDA Discussion Prompts Voluntary Withdrawal of BLA for I-DXd in ES-SCLC
4
SBRT Matches Disease Control of Prostatectomy in Localized Prostate Cancer
5